Skip to main
TNYA
TNYA logo

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc. is demonstrating promising advancements in its gene therapy programs, particularly with the demonstration of consistent improvements in left ventricular posterior wall thickness (LVPWT) and left ventricular mass index (LVMI) among trial participants. Positive safety reviews from independent Data Safety and Monitoring Boards for its ongoing pivotal trials indicate strong regulatory progress and growing confidence in its therapeutic candidates, which could enhance the potential for accelerated approval pathways. Additionally, the observed increases in MyBP-C protein levels and favorable patient outcomes suggest that the company's innovative approaches in addressing heart disease may lead to significant future clinical and financial success.

Bears say

The financial outlook for Tenaya Therapeutics, Inc. is negatively impacted by potential delays in transitioning its preclinical assets to clinical stages, which could significantly affect market sentiment and lead to downward revisions in financial projections. Additionally, challenges related to manufacturing capacity for AAV-based gene therapy products pose substantial risks, as these products are complex and difficult to produce, threatening both development timelines and commercialization efforts. Furthermore, observed variability in patient responses during trials, including a mean reduction of 28% in LVPWT values, raises concerns regarding the efficacy and safety of the company's therapy candidates, further complicating the financial landscape for Tenaya.

Tenaya Therapeutic (TNYA) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.